Form 4: Immunovant CEO Sells Shares to Cover Tax Obligations After RSU Vesting

Immunovant CEO Peter Salzmann sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On July 17, 2024, Immunovant CEO Peter Salzmann sold 8,175 shares of common stock at a weighted average price of $29.64.
• He also sold 510 shares at a weighted average price of $30.55.
• These sales were to cover tax withholding obligations related to the vesting of 15,239 restricted stock units (RSUs) on July 12, 2024, which were part of a grant of 243,832 RSUs on April 12, 2023.
• The sales were mandated by Immunovant's policy requiring 'sell to cover' transactions for tax obligations and do not represent discretionary transactions by Salzmann.
• Following these transactions, Salzmann beneficially owns 1,023,412 shares of Immunovant common stock.

Sentiment

Score: 5

Explanation: The document describes a routine transaction (selling shares to cover taxes on vested RSUs). It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Executive stock sales are a common occurrence, particularly when RSUs vest, as executives often sell shares to cover the associated tax obligations. This is a standard practice and doesn't necessarily indicate a lack of confidence in the company.

Stakeholder Impact

• The sale of shares by the CEO could have a minor, temporary impact on the stock price, but is unlikely to have a significant long-term effect.

Key Dates